12:00 AM
 | 
Apr 10, 2000
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

AVI preclinical data

AVII said that its Neugene antisense compound against c-myc significantly decreased tumor growth in...

Read the full 47 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >